Clinical Research

Found 142,909 articles

• Spago Nanomedical has Submitted Application to Start Tumorad(R) Clinical Phase I/IIa Study

  5/23/2023

  Spago Nanomedical AB announced that the final step in the preparations for the clinical phase I/IIa trial in cancer patients, Tumorad-01, with its leading candidate drug 177Lu-SN201 has begun in Australia.

• 

  Biopharma Targets the Untapped Potential of the Human Healthspan

  5/22/2023

  More than $5 billion poured into the longevity space in 2022, and experts say the science is now primed to make a real difference in extending human healthspan.

• Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

  5/22/2023

  Enveric Biosciences, Inc. has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders.

• GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators

  5/22/2023

  GRI Bio, Inc. today provided a business outlook and highlighted upcoming milestones for its innovative pipeline of NKT cell modulators in development.

• ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

  5/22/2023

  ABVC BioPharma, Inc. today announced that the Vitrargus® Phase II study at the Sydney Eye Hospital in New South Wales, Australia received ethical approval from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) on May 15, 2023.

• Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

  5/22/2023

  Clearmind Medicine Inc. today announced the selection of its first U.S. site for the company’s Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD").

• Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub & Collaborations with Leading Experts in Protein Design & Cancer Immunotherapy

  5/22/2023

  Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, announced the expansion of its research facilities and new collaborations with leading scientists at Fred Hutchinson Cancer Center and the Institute for Protein Design at the University of Washington School of Medicine.

• Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

  5/22/2023

  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

• Yaral Pharma Partners With EVERSANA to Support the Commercialization of Its Expanding Generics Portfolio

  5/22/2023

  Yaral Pharma Inc. today announced its expanding partnership with EVERSANA ® , a leading provider of commercialization services to the global life sciences industry, as its key commercialization partner to support the expansion of its portfolio of pain and endocrinology products in the U.S.

• ATCOR Launches New 2,000-Patient Longitudinal Retrospective Study for Heart Health

  5/22/2023

  ATCOR Medical announced it has launched a single-center retrospective study of 2,000 hypertensive patients to identify associated care outcomes resulting from the routine monitoring of central aortic blood pressure and peripheral blood pressure.

• Circulating Tumor Cells Isolated with Unique TellDx Technology May Help Predict Response to Therapy in Patients with Progressive Metastatic Breast Cancer

  5/22/2023

  TellBio, Inc. announces publication of data that show the utility of CTCs isolated with TellDx to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a cohort of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who progress on endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibition.

• Lumicell Announces FDA Acceptance and Priority Review of New Drug Application for LUMISIGHT™ Optical Imaging Agent for Breast Cancer

  5/22/2023

  Lumicell, Inc today announced the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for the New Drug Application (NDA) for the LUMISIGHT™ Optical Imaging Agent and accepted the Premarket Approval (PMA) application for the Lumicell™ Direct Visualization System (DVS).

• Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer

  5/22/2023

  Panbela Therapeutics, Inc. today announced it has entered into a clinical trial agreement with Moffitt Cancer Center for a Phase I/II program in STK11 mutant non-small cell lung cancer (NSCLC).

• Siblings with autism share more of dad's genome, not mom's

  5/22/2023

  Scientists long thought that siblings born with ASD share more of their mother's genome than their father's.

• Microbot Medical Achieved 100% Success Rate for LIBERTY in Extensive Pre-Clinical Animal Study Performed by Leading European Physicians

  5/22/2023

  Microbot Medical Inc., the developer of the LIBERTY® Surgical Robotic System, the first single-use endovascular robotic system, announced a highly successful extended joint pre- clinical animal study held at a leading European-based research lab.

• Twist Bioscience Launches Portfolio of RNA Sequencing Tools

  5/22/2023

  Twist Bioscience Corporation today announced the launch of a portfolio of RNA sequencing tools, which includes the Twist RNA Exome, Twist RNA Library Prep Kit and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit, as well as custom target enrichment capabilities for RNA and whole transcriptome sequencing.

• Novozymes OneHealth Presence Felt at 2023 China Gut Conference, Featuring the Theme, "Innovation, Collaboration, Symbiosis"

  5/22/2023

  The 2023 China Gut Conference, held from May 20-22, 2023, successfully wrapped up at the China National Convention Center in Beijing.

• Intellego Technologies Partners With HAI Solutions for a Novel Application of Ultraviolet Photochromic Ink for an Intravenous Port Disinfection Technology to Mitigate Risk of Contamination

  5/22/2023

  Intellego Technologies and HAI Solutions are proud to announce a strategic partnership that is designed to improve the quality and safety of intravenous (IV) vascular access.

• Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)

  5/22/2023

  Tonix Pharmaceuticals Holding Corp. today announced that it has entered into a research collaboration agreement to evaluate the effect of TNX-1900 (intranasal potentiated oxytocin) on capsaicin- or electrical stimulation-induced forehead dermal blood flow in healthy female human volunteers.

• BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

  5/22/2023

  BridgeBio Pharma, Inc. presented promising positive data from six participants dosed in CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease.